Medical Advocates
Bevirimat(PA-457)
  Main Page

New and Noteworthy
Journal Data
Conference Data


 		  
ARV Investigational  Drugs Main Page Drugs Main Page Home Page      
Last Update:  March 11, 2015 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
November 2010
 
Journal Papers, Abstracts, and Commentaries
 
General Reports
 
 
An Oral Human Drug Absorption Study to Assess the Impact of Site of Delivery on the Bioavailability
of Bevirimat.
Connor A, Evans P, Doto J, et al
J Clin Pharmacol. 2009 Mar 20.
 Abstract

A WEEK IN REVIEW FEATURED REPORT
Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.
 Martin DE, Salzwedel K, Allaway GP.
Antivir Chem Chemother. 2008;19(3):107-13.
 Abstract
 
  FULL-TEXT ARTICLE
Activation and inhibition of the proteasome by betulinic acid and its derivatives.
Huang L, Ho P, Chen CH.
 FEBS Lett. 2007 Oct 16;581(25):4955-9.
 Paper
 
  Glucuronidation of anti-HIV drug candidate bevirimat: identification of human UDP-glucuronosyltransferases
and species differences.
Wen Z, Martin DE, Bullock P, et al
 Drug Metab Dispos. 2007 Mar;35(3):440-8.
 Abstract
 
  Determinants of activity of the HIV-1 maturation inhibitor PA-457.
Li F, Zoumplis D, Matallana C, et al
 Virology. 2006 Dec 5-20;356(1-2):217-24
 Abstract
 
  Structural characterization of anti-HIV drug candidate PA-457 [3-O-(3',3'-dimethylsuccinyl)-betulinic acid]
and its acyl glucuronides in rat bile and evaluation of in vitro stability in human and animal liver microsomes
and plasma.
Wen Z, Stern ST, Martin DE,
Drug Metab Dispos. 2006 Sep;34(9):1436-42
 Abstract
 
  FULL-TEXT PDF ARTICLE
 PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.
 Li F, Goila-Gaur R, Salzwedel K,  et al
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13555-60.
 Paper
 
Pharmacokinetics
 
 
Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers:
An open-label, parallel-group study.
Martin DE, Galbraith H, Schettler J, Ellis C, Doto J.
Clin Ther. 2008 Oct;30(10):1794-805.
 Abstract
 
Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Martin DE, Blum R, Doto J, et al
 Clin Pharmacokinet. 2007;46(7):589-98.
 Abstract
 
Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation,
in healthy volunteers.
 Martin DE, Blum R, Wilton J, et al
Antimicrob Agents Chemother. 2007 Sep;51(9):3063-6.
Abstract

Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: An open-label,
parallel-group study.
Martin DE, Galbraith H, Schettler J,et al
 Clin Ther. 2008 Oct;30(10):1794-805
 Abstract
 
Resistance
 
 
A WEEK IN REVIEW FEATURED REPORT
FULL-TEXT PDF ARTICLE
 Improved Bevirimat resistance prediction by combination of structural and sequence-based
classifiers.
Dybowski JN, Riemenschneider M, Hauke S,  et al
 BioData Min. 2011 Nov 14;4(1):26
 Paper

In vitro selection of clinically-relevant bevirimat resistance mutations revealed by ""deep"
sequencing of serially-passaged, quasispecies-containing recombinant HIV-1.
Knapp DJ, Harrigan PR, Poon AF,  et al
J Clin Microbiol. 2010 Nov 17.
 Abstract

Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease
inhibitor-experienced patients.
Malet I, Wirden M, Derache A, et al
 AIDS. 2007 Apr 23;21(7):871-3
 Abstract

FULL-TEXT ARTICLE
In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457
(Bevirimat).
Adamson CS, Ablan SD, Boeras I,  et al
 J Virol. 2006 Nov;80(22):10957-71.|
 Paper
 
Viral Dynamics
 
  FULL-TEXT ARTICLE
Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics
of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human
immunodeficiency virus infection.
Smith PF, Ogundele A, Forrest A,
 Antimicrob Agents Chemother. 2007 Oct;51(10):3574-81.
 Paper
Conference Reports, Abstracts,  and Posters
     
4th IAS Conference on HIV Pathogenesis, Treatment and Prevention
 
  Multiple dosing of the novel HIV-1 maturation inhibitor bevirimat (BVM): aggregate advers...
 McCallister S, Doto J.
Abstract
 
Characterization of PA1050040, a second generation HIV-1 maturation inhibitor
 Kilgore N.  , Reddick M., Zuiderhof M.
 Abstract
 
Minimal effect of ritonavir (RTV) on the pharmacokinetics (PK) of bevirimat (BVM) in healt...
 Martin D. , Galbraith H , Ellis C.
Abstract
 
The disposition of 14C-bevirimat (BVM) in rats and marmosets
 Bullock P, Smart C, Larsen D.
Abstract

ARV Investigational  Drugs Main Page Drugs Main Page Home Page      

Bevirimat